IDERA PHARMACEUTICALS INC (IDRA) Stock Price, Quote, News and Overview
NASDAQ:IDRA - Nasdaq - US45168K4058 - Common Stock - Currency: USD
IDRA Quote, Performance and Key Statistics
0.425
-0.12 (-21.57%)
The current stock price of IDRA is 0.425 USD. In the past month the price increased by 54.55%. In the past year, price decreased by -28.08%.
IDRA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IDRA
Company Profile
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101. The company is also focused on rare, orphan pulmonary and rheumatic diseases.
Company Info
IDERA PHARMACEUTICALS INC
505 Eagleview Boulevard, Suite 212
Exton PENNSYLVANIA 19341 US
CEO: Vincent J. Milano
Employees: 13
Company Website: http://www.iderapharma.com/
Phone: 14843481600.0
IDERA PHARMACEUTICALS INC / IDRA FAQ
What is the stock price of IDERA PHARMACEUTICALS INC today?
The current stock price of IDRA is 0.425 USD. The price decreased by -21.57% in the last trading session.
What is the ticker symbol for IDERA PHARMACEUTICALS INC stock?
The exchange symbol of IDERA PHARMACEUTICALS INC is IDRA and it is listed on the Nasdaq exchange.
On which exchange is IDRA stock listed?
IDRA stock is listed on the Nasdaq exchange.
What is IDERA PHARMACEUTICALS INC worth?
IDERA PHARMACEUTICALS INC (IDRA) has a market capitalization of 25.08M USD. This makes IDRA a Nano Cap stock.
How many employees does IDERA PHARMACEUTICALS INC have?
IDERA PHARMACEUTICALS INC (IDRA) currently has 13 employees.
What are the support and resistance levels for IDERA PHARMACEUTICALS INC (IDRA) stock?
IDERA PHARMACEUTICALS INC (IDRA) has a support level at 0.41. Check the full technical report for a detailed analysis of IDRA support and resistance levels.
Should I buy IDERA PHARMACEUTICALS INC (IDRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IDRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IDRA, evaluating the profitability, health, valuation and growth aspects
- IDERA PHARMACEUTICALS INC (IDRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IDERA PHARMACEUTICALS INC (IDRA) Sales and EPS estimates to see what analysts future expectations are.
- IDERA PHARMACEUTICALS INC (IDRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IDERA PHARMACEUTICALS INC (IDRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- IDERA PHARMACEUTICALS INC (IDRA) Stock Chart to make your own analysis
- IDERA PHARMACEUTICALS INC (IDRA) Latest news and press-releases to stay up to date.
Does IDERA PHARMACEUTICALS INC (IDRA) stock pay dividends?
IDRA does not pay a dividend.
When does IDERA PHARMACEUTICALS INC (IDRA) report earnings?
IDERA PHARMACEUTICALS INC (IDRA) will report earnings on 2023-03-29.
What is the Price/Earnings (PE) ratio of IDERA PHARMACEUTICALS INC (IDRA)?
The PE ratio for IDERA PHARMACEUTICALS INC (IDRA) is 0.18. This is based on the reported non-GAAP earnings per share of 2.34 and the current share price of 0.425 USD. Check the full fundamental report for a full analysis of the valuation metrics for IDRA.
IDRA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to IDRA. When comparing the yearly performance of all stocks, IDRA is a bad performer in the overall market: 74.57% of all stocks are doing better.
IDRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IDRA. IDRA has a bad profitability rating. Also its financial health evaluation is rather negative.
IDRA Financial Highlights
Over the last trailing twelve months IDRA reported a non-GAAP Earnings per Share(EPS) of 2.34. The EPS increased by 160.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
IDRA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to IDRA. The Buy consensus is the average rating of analysts ratings from 6 analysts.